This study suggests that for individuals with type 1 diabetes and A1c above 8%, CGM and SMBG with intensive insulin therapy is a cost-effective alternative to SMBG alone with intensive insulin therapy. This evidence concerns the gene INS and type 1 diabetes mellitus.